China is the world's second-largest medical device market, but entering it requires navigating one of the most demanding regulatory systems in the world. NMPA — China's National Medical Products Administration, formerly CFDA — oversees all medical device registrations and has significantly tightened standards since 2021 reforms.

This guide draws on the direct experience of our team, who served as senior NMPA review specialists before joining the consulting side. We know what reviewers look for, where dossiers commonly fail, and how to position your device for the fastest viable path to registration.

1. Understanding China's Medical Device Classification System

Every NMPA registration strategy starts with correct classification. China uses a three-tier risk-based system under the Medical Device Supervision and Administration Regulations (医疗器械监督管理条例, MDSAM Regulations, revised 2021).

Important: Classification is determined by NMPA's Medical Device Classification Catalogue (分类目录). Misclassifying your device — especially registering at a lower class than NMPA expects — is one of the leading causes of early-stage rejections. We recommend commissioning a formal classification opinion before starting any registration work.

2. Who Must Register? Scope and Applicability

Any medical device intended to be sold, distributed, or used commercially in mainland China must be registered or filed with NMPA before market entry. This includes:

• Devices sold through Chinese distributors or importers
• Devices supplied to Chinese hospitals, clinics, or health facilities
• Devices used in clinical trials conducted in China (subject to separate IND-equivalent approval)
• Software as a Medical Device (SaMD) when meeting device definition criteria

Devices in transit, for personal use in small quantities, or donated for emergency relief may be exempt — but consult legal counsel before assuming exemption applies.

3. The China Authorized Agent (授权代理人): What You Need to Know

This is the most misunderstood requirement for foreign manufacturers. Under Article 36 of the MDSAM Regulations, all foreign manufacturers must appoint a China Authorized Agent (中国境内授权代理人) before applying for NMPA registration.

What the Authorized Agent Does

• Holds the NMPA registration certificate on behalf of the foreign manufacturer
• Is the legal point of contact for NMPA — all regulatory correspondence goes through them
• Manages post-market surveillance obligations, including adverse event reporting
• Handles product recalls and field safety corrective actions in China
• Files annual reports and maintains post-market regulatory compliance

Who Can Serve as Authorized Agent?

The agent must be a Chinese legal entity with a valid business license. They do not need to be a medical device company — any registered Chinese business can serve as agent. In practice, most foreign manufacturers use one of three models:

1. Regulatory consultancy as agent — A specialist firm (like Nexiv Global) assumes the agent role, providing full regulatory expertise alongside the legal responsibility
2. Chinese distributor as agent — Practical if you have a committed distribution partner, but creates concentration risk if the relationship changes
3. Own Chinese subsidiary as agent — Appropriate if you're establishing a Chinese entity anyway, but not required

The Authorized Agent is not just an administrative formality. They carry real legal liability under Chinese law. Choosing an agent without deep regulatory expertise is a risk — deficiency letters go to them, and their responses directly determine your registration timeline.

4. Prerequisites Before You File

NMPA registration cannot begin until certain prerequisites are in place. Many foreign manufacturers underestimate the time these take to arrange.

ISO 13485 Certification

NMPA requires a valid ISO 13485 quality management system certificate covering the device types to be registered. The certificate must be issued by an accredited certification body and must be current throughout the registration process. If your ISO 13485 is expiring during registration, plan for renewal — a lapsed certificate will halt your application.

China-Recognized Laboratory Testing

For most Class II and all Class III devices, NMPA requires testing at laboratories on its official recognition list (国家认可实验室). Tests conducted at ISO-accredited labs outside China — even globally respected institutions — generally cannot be substituted. Required testing typically includes:

• Electrical safety (IEC 60601 series, as applicable)
• Electromagnetic compatibility (EMC)
• Biocompatibility (ISO 10993 series, for patient-contacting devices)
• Device-specific performance tests per applicable NMPA guidance

Coordinate laboratory testing early — popular NMPA-recognized labs in Beijing, Shanghai, and Shenzhen often have 3–6 month waitlists.

Clinical Evaluation Data

Class II and III devices require a clinical evaluation report (临床评价报告). NMPA accepts three pathways:

1. Literature-based evaluation — Systematic review of published clinical evidence for the device or substantially equivalent predicate. Viable for many Class II devices with established clinical literature.
2. Clinical trial data — Required for Class III devices without established predicates, and for some novel Class II technologies. China-based clinical trials typically required unless exemptions apply.
3. Equivalence to domestic registered product — Demonstrating equivalence to an already-registered Chinese device can streamline the clinical evaluation requirement, but requires careful predicate selection.

5. The 7-Step NMPA Registration Process

1. 1
   Device Classification and Pathway Assessment Confirm classification in the NMPA catalogue, assess whether a novel device guidance document applies, determine if clinical trial exemption is available, and plan the overall strategy. Budget 2–4 weeks for a thorough classification opinion.
2. 2
   Appoint China Authorized Agent Execute an agency agreement specifying responsibilities. The agent's business license and appointment letter must be included in the registration dossier. Choose the agent before laboratory testing starts — the agent's name appears on test reports.
3. 3
   Arrange China Laboratory Testing Identify applicable NMPA-recognized labs, submit test applications, ship test samples, and complete testing. This phase takes 3–9 months depending on device complexity and lab scheduling. It is typically the longest single step for Class II devices.
4. 4
   Prepare the Technical Dossier Compile all registration documents: device description, intended use, risk analysis, biocompatibility data, lab test reports, clinical evaluation, quality system evidence, manufacturing info, and labeling. All documents must be in Simplified Chinese — translation quality matters significantly for review speed.
5. 5
   Submit via NMPA Online Portal and Pay Government Fees Applications are submitted through NMPA's electronic submission system. Government fees are paid after formal acceptance. Class I filings go to the provincial drug administration; Class II/III go to NMPA nationally (or provincial for some Class II).
6. 6
   Technical Review and Deficiency Response NMPA reviewers assess the dossier — typically 6–18 months for Class II, 18–36+ months for Class III. Deficiency letters (补正意见) are common; the typical dossier receives 1–3 rounds. Each round allows a response window (typically 3–6 months). Response quality is critical — vague or incomplete answers trigger additional rounds.
7. 7
   Receive Registration Certificate and Post-Market Setup Upon approval, NMPA issues the registration certificate (医疗器械注册证) valid for 5 years. Immediately establish post-market obligations: adverse event reporting system, complaint handling procedures, and annual report schedule. Renewal must begin 6 months before certificate expiry.

6. Registration Timeline and Cost Summary

The timeline and cost figures below represent realistic ranges based on our team's direct experience managing NMPA submissions. They assume a well-prepared dossier and competent deficiency response — both factors that vary significantly between applicants.

7. Common Reasons NMPA Applications Fail

Based on our team's review experience, the most common causes of deficiency letters and application rejection are:

• Insufficient clinical evaluation — Literature reviews that don't meet NMPA's evidence standards, or clinical equivalence claims without adequate comparative data
• Non-NMPA-recognized lab testing — Submitting test reports from non-recognized labs, or using outdated test standards
• Translation quality issues — Mistranslations or inconsistencies in technical terminology that lead reviewers to request clarification
• Risk analysis gaps — ISO 14971 risk files that don't address China-specific use scenarios or hazards
• Labeling non-compliance — Missing required information, incorrect format, or labeling that doesn't match the registered device description
• Scope mismatch — ISO 13485 certificate that doesn't cover the device types or manufacturing scope of the products being registered

8. CE Mark and FDA Clearance: What Transfers to NMPA

China does not have mutual recognition agreements with the EU or the United States. NMPA conducts fully independent reviews. However, existing regulatory clearances can provide useful supporting evidence:

• CE technical documentation — The MDD/MDR technical file can serve as the foundation for the NMPA dossier, though it requires reorganization to meet NMPA structure requirements
• FDA 510(k) or PMA data — Clinical data submitted to FDA can often be repurposed for the NMPA clinical evaluation, particularly for Class II devices
• Testing data — Some IEC 60601 and ISO test data may be accepted if the lab is on NMPA's recognized list; otherwise, repeat testing in China is required

A realistic assessment: companies with strong CE technical documentation typically save 3–6 months on dossier preparation compared to starting from scratch. The China lab testing requirement remains regardless.

9. Post-Registration Obligations

Registration is the beginning, not the end, of your NMPA compliance journey. Foreign manufacturers (through their Authorized Agent) must:

• Report serious adverse events within 30 days (or 5 days for life-threatening events)
• File annual summary reports (年度报告) covering complaints, adverse events, and field actions
• Notify NMPA and obtain approval for significant device changes (design, manufacturing, labeling)
• Maintain post-market surveillance records
• Initiate registration renewal no later than 6 months before certificate expiry (5-year term)

Non-compliance with post-market obligations has led to certificate suspensions and market withdrawals — regulators take these seriously since the 2021 regulatory reform.

10. Special Pathways and Expedited Options

Breakthrough Device Designation

NMPA operates a Breakthrough Device Designation (创新医疗器械特别审查程序) for novel devices that address unmet clinical needs with innovative technology. Qualifying devices receive dedicated review resources, rolling submission, and enhanced NMPA communication. The pathway can reduce Class III review time by 20–40% for devices that qualify.

Priority Review Designation

Devices addressing emergency situations or rare diseases may qualify for priority review designation, compressing standard timelines.

Free Trade Zone (FTZ) Pilot Programs

China's Free Trade Zones — particularly Hainan and certain Shanghai FTZ areas — have piloted expedited access programs for some medical device categories. These are still limited in scope but worth monitoring for relevant device types.

中国是全球第二大医疗器械市场，但进入中国需要应对全球最严格的监管体系之一。NMPA（原CFDA）负责所有医疗器械注册审批，自2021年监管改革以来标准持续提高。

本指南由我们团队编写。我们的核心成员曾担任NMPA高级审评专家，拥有亲历审评工作的第一手经验，深知审评员的关注重点，以及哪些技术文件最容易出现问题。

一、中国医疗器械分类体系

所有NMPA注册策略的起点是正确分类。中国依据《医疗器械监督管理条例》（2021年修订版）实行三类风险分级管理制度。

注意：产品类别依据NMPA《医疗器械分类目录》确定。错误分类（尤其是将产品定为低于审评预期的类别）是最常见的早期驳回原因之一。建议在启动注册工作前委托专业机构出具正式分类意见。

二、境内授权代理人（授权代理人）：最容易被误解的要求

根据《医疗器械监督管理条例》第三十六条，所有境外制造商必须在中国境内指定授权代理人，方可向NMPA申请注册。

授权代理人的职责

• 持有NMPA颁发的医疗器械注册证
• 作为与NMPA沟通的法定联络人，承接全部监管往来
• 履行上市后监管义务，包括不良事件报告
• 负责在中国境内处理产品召回及现场安全纠正行动
• 提交年度总结报告，保持注册后持续合规

谁可以担任授权代理人？

授权代理人必须是持有有效营业执照的中国法人实体，不要求是医疗器械企业。实践中，境外企业通常采用以下三种模式之一：

1. 监管咨询公司代理——由专业咨询机构（如Nexiv Global）承担代理角色，同时提供全程监管支持
2. 中国经销商代理——若已有合作伙伴，可由其承担；但需注意合作关系变化带来的风险
3. 自设中国子公司代理——如有意在中国设立实体，可由子公司担任；但并非强制要求

授权代理人不只是行政手续。在中国法律框架下，代理人承担真实法律责任。补正意见发至代理人，其回复质量直接决定你的注册时间线。选择缺乏专业监管能力的代理人，风险极高。

三、申报前的必备条件

ISO 13485认证

NMPA要求提供覆盖申报产品类型的有效ISO 13485质量管理体系认证证书。证书必须由认可认证机构颁发，并在注册全程保持有效。如认证证书即将到期，需提前安排续期——证书失效将直接导致申请中断。

中国认可实验室检测

多数二类器械和全部三类器械须在国家认可实验室（国家认可实验室名录）完成检测。境外ISO认可实验室出具的检测报告，通常不被NMPA接受作为替代。常规检测项目包括：

• 电气安全（适用时按IEC 60601系列标准）
• 电磁兼容（EMC）
• 生物相容性（接触患者的器械，按ISO 10993系列）
• 按NMPA适用指导原则执行的产品性能检测

建议尽早安排实验室预约——北京、上海、深圳的热门认可实验室排队周期通常为3–6个月。

临床评价数据

二类和三类器械均需提交临床评价报告（临床评价报告）。NMPA认可三种路径：文献评价、临床试验数据、与已注册国产器械等同性论证。

四、注册全流程（7个步骤）

1. 1
   产品分类与路径评估 确认分类目录归属，评估是否适用创新医疗器械特别审查程序，判断能否豁免临床试验，制定整体策略。建议留出2–4周完成正式分类意见。
2. 2
   指定境内授权代理人 签署代理协议，明确各方职责。代理人营业执照及授权书须纳入申报资料。建议在开始实验室检测之前完成指定——检测报告须载明代理人信息。
3. 3
   安排中国认可实验室检测 确定适用认可实验室，提交检测申请，寄送样品，完成全部检测。该阶段耗时3–9个月，视器械复杂程度与实验室排期而定，通常是二类器械注册周期最长的单一环节。
4. 4
   准备技术申报资料 汇编全套注册文件：产品描述、预期用途、风险分析、生物相容性数据、检测报告、临床评价、质量体系证明、生产信息及中文标签。所有文件须以简体中文提交——翻译质量直接影响审评效率。
5. 5
   通过NMPA网上平台提交申请，缴纳政府注册费 申请材料通过NMPA电子申报系统提交。形式审查通过后缴纳注册费。第一类备案递交省级药品监管部门；第二类/第三类向NMPA国家局申报（部分二类可省级受理）。
6. 6
   技术审评与补正意见回复 NMPA审评员对申报资料进行技术审评——二类通常需6–18个月，三类需18–36个月以上。补正意见（补正意见）是常态，典型申请会经历1–3轮。每轮回复窗口通常为3–6个月。回复质量至关重要——模糊或不完整的答复会触发新一轮补正。
7. 7
   取得注册证，建立上市后管理体系 经批准后，NMPA颁发《医疗器械注册证》，有效期5年。同步建立上市后合规体系：不良事件报告系统、投诉处理程序及年度总结报告机制。注册证届满前6个月须启动续期。

五、注册时间与费用汇总

六、申请失败的常见原因

• 临床评价不充分——文献综述不满足NMPA证据标准，或等同性论证缺乏对比数据支撑
• 非认可实验室检测报告——提交境外实验室报告，或使用过时的检测标准
• 翻译质量问题——技术术语翻译错误或前后不一致，导致审评员需要进一步澄清
• 风险分析缺失——ISO 14971风险文件未覆盖中国特定使用场景或危害
• 标签不合规——缺少必要信息、格式不符，或与注册资料中的产品描述不一致
• ISO 13485范围不匹配——认证证书未覆盖申报产品类型或生产范围

七、上市后合规义务

取得注册证只是合规之旅的起点。境外制造商（通过授权代理人）须持续履行以下义务：

• 严重不良事件30天内报告（危及生命情形5天内报告）
• 每年提交年度总结报告，涵盖投诉、不良事件及现场行动
• 产品重大变更须事先向NMPA申报并获批
• 建立并维护上市后监测记录
• 注册证到期前6个月启动续期程序（有效期5年）